Clinical Trials on Japanese Encephalitis Vaccine in Germany

Total 70 results

Valneva Austria GmbH

Completed

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Austria, Germany
Valneva Austria GmbH

Completed

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Japanese Encephalitis

Australia, United States, Germany
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
Novartis Vaccines

Completed

Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects

Japanese Encephalitis | Rabies

Austria, Germany, Switzerland
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)

Vaccines, Combined | Hexavalent Vaccine

Germany, Italy, Spain
Pfizer

Completed

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Vaccines, Pneumococcal Conjugate Vaccine

United States, Spain, France, Canada, Germany, Czechia, Sweden, Belgium, Poland, Netherlands
Novartis
Novartis Vaccines

Completed

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Japanese Encephalitis | Rabies | Yellow Fever | Meningococcal Disease | Typhoid | Meningococcal Meningitis

Czech Republic, Germany
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Japanese | Caucasian

Germany
Novartis
Novartis Vaccines

Completed

Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children

Encephalitis, Tick-Borne

Germany
Novartis
Novartis Vaccines

Completed

Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults

Encephalitis, Tick-Borne

Germany
University Hospital, Bonn
Octapharma; Astellas Pharma GmbH

Unknown

Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis

Rasmussen Encephalitis

Germany
Pfizer

Completed

Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)

Encephalitis, Tick-Borne

Austria, Germany, Poland
Novartis Vaccines

Completed

An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE

Tick Borne Encephalitis (TBE)

Germany
Pfizer

Completed

Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

Tick-borne Encephalitis

Austria, Germany, Poland
Pfizer

Completed

TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)

Encephalitis, Tick-Borne

Germany, Austria, Poland
Novartis
Novartis Vaccines

Completed

Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years

Encephalitis, Tick-Borne

Germany
Pfizer

Completed

FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

Encephalitis, Tick-borne

Germany
Charite University, Berlin, Germany

Completed

Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis

Anti-NMDA Receptor Encephalitis

Germany
Pfizer

Completed

FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years

Encephalitis, Tick-borne

Austria, Germany
Pfizer

Completed

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.

Tick-borne Encephalitis

Germany
Pfizer

Completed

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.

Tick-borne Encephalitis

Austria, Germany
Universitätsklinikum Hamburg-Eppendorf
Goethe University; German Federal Ministry of Education and Research; Bernhard... and other collaborators

Not yet recruiting

Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure (PREPARE)

Ebola Vaccine

Germany
Biogen
Elan Pharmaceuticals

Terminated

Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) (IRIS)

Leukoencephalopathy, Progressive Multifocal | Immune Reconstitution Inflammatory Syndrome

Germany, United States
Biogen
Elan Pharmaceuticals

Terminated

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Progressive Multifocal Leukoencephalopathy

United States, Brazil, Italy, Spain, Germany
Biogen

Terminated

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Progressive Multifocal Leukoencephalopathy

United States, Germany
Pfizer

Terminated

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Meningococcal Vaccine

Spain, Germany, Greece
Pfizer

Completed

A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Meningococcal Vaccine

Spain, Germany, Finland, Czechia, Poland, Denmark, Sweden
Ludwig-Maximilians - University of Munich
Freie Universität Berlin

Completed

Evaluation of a TDM Program for Intensive Care Patients in the Cerebrospinal Fluid (EMIL)

Ventriculitis, Infectious

Germany
Pfizer

Completed

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Meningococcal Vaccine

United States, Canada, Finland, Italy, Poland, United Kingdom, Czech Republic, Germany
Hannover Medical School
Universitätsklinikum Hamburg-Eppendorf; German Center for Infection Research; IDT Biologika

Terminated

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

COVID-19 Vaccines

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza, Vaccine

Germany
Jena University Hospital

Recruiting

Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (Generate-Boost)

Autoimmune Encephalitis

Germany
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza | Vaccine

Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Vaccines, Pneumococcal

Germany
Hannover Medical School
Else Kröner Fresenius Foundation

Recruiting

Priming of the NEonatal Immune System by Transfer of Maternal Immunity (NEST)

COVID-19 | Respiratory Infections in Children | Maternal Vaccine Exposure

Germany
Masaryk University

Recruiting

COVID-19 Vaccines Safety Tracking (CoVaST)

Adverse Reaction to Vaccine | COVID19 Vaccine

Poland, Canada, United States, Croatia, Czechia, Estonia, Ethiopia, Germany, Ghana, Mexico, Portugal, Russian Federation, Serbia, Slovenia
Bavarian Nordic

Completed

Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects

Smallpox

Germany
Pfizer

Terminated

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation (STRIVE)

Staphylococcal Vaccine

United States, Spain, United Kingdom, Canada, France, Japan, Germany, Hungary, Austria, Bulgaria, Sweden
University Hospital Tuebingen

Completed

Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)

COVID-19 Vaccine

Germany
UCB Biopharma SRL

Terminated

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

Seasonal Influenza Vaccine

Germany
University of Rostock

Completed

Neurocognitive Impairment in Pediatric Patients With Meningoencephalitis and Sepsis-associated Encephalopathy (NCIPED)

Central Nervous System Diseases | Delirium | Brain Injuries | Critical Illness | Encephalopathy | Inflammatory Disease

Germany
Pfizer

Completed

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Meningitis | Meningococcal Vaccine | rLP2086 | Repevax | N Meningitidis Serogroup B

Germany, Finland, Poland
Novartis Vaccines

Completed

Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

Seasonal Influenza | Vaccine

Germany
Heinrich-Heine University, Duesseldorf

Recruiting

Vaccination Against COVID-19 in Chronic Kidney Disease

Vaccine Response Impaired | Chronic Kidney Disease Stage 5 on Dialysis | Chronic Kidney Disease Stage 5 With Transplant

Germany
Heinrich-Heine University, Duesseldorf

Recruiting

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine (CIRMS)

Multiple Sclerosis, Relapsing-Remitting | Vaccine Response Impaired

Germany
BioNTech SE

Active, not recruiting

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults

RNA Virus Infections | Virus Diseases | Vaccine Adverse Reaction | Infection Viral | Infections, Respiratory | Protection Against COVID-19 and Infections With SARS CoV 2

Germany

3

Subscribe